Although response rates to EGFR-targeted therapies in patients with advanced WT KRAS CRC have been disappointing, combined blockade of EGFR and glutaminolysis has exhibited promising efficacy in preclinical studies [7], and is being currently explored clinically in CRC (NCT 03263429). Here, EGFR is linked to colorectal carcinoma.